文献速递脑血管病神经重症与神经感染

脑出血初始收缩压≥220 mmHg强化降压的结局:随机试验事后分析

Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure: Post Hoc Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2020-01-01

该研究为ATACH-II试验事后分析,纳入999例脑出血患者,比较强化降压(目标110-139 mmHg)与标准降压(目标140-179 mmHg)在初始收缩压≥220 mmHg与<220 mmHg患者中的差异。

要点

  • 初始收缩压≥220 mmHg的脑出血患者,强化降压增加24小时内神经功能恶化风险。
  • 强化降压组肾脏不良事件率显著高于标准降压组。
  • 两组90天死亡或严重残疾率无显著差异。

核心结论

  • 初始收缩压≥220 mmHg的脑出血患者中,强化降压与24小时内神经功能恶化率更高相关,且未减少血肿扩大或改善90天死亡或严重残疾,应谨慎推广强化降压推荐。

研究设计与样本

  • ATACH-II多中心随机临床试验的事后分析,于2019年11月进行,数据来自2011年5月至2015年9月。
  • 共筛查8532例,999例脑出血且初始收缩压≥180 mmHg、症状发作4.5小时内随机化的患者纳入分析。
  • 干预为静脉尼卡地平滴定至目标血压。

主要发现

  • 肾脏严重不良事件率两组无差异。

关键数值与推荐

  • 强化降压目标为110-139 mmHg,标准降压目标为140-179 mmHg。

临床怎么用

  • 对初始收缩压≥220 mmHg的脑出血患者,应谨慎采用强化降压至110-139 mmHg,需权衡神经功能恶化和肾脏不良事件风险。

局限性

  • 本研究为事后分析,初始收缩压≥220 mmHg亚组样本量较小(228例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The safety and efficacy of intensive systolic blood pressure reduction in patients with intracerebral hemorrhage who present with systolic blood pressure greater than 220 mm Hg appears to be unknown. OBJECTIVE: To evaluate the differential outcomes of intensive (goal, 110-139 mm Hg) vs standard (goal, 140-179 mm Hg) systolic blood pressure reduction in patients with intracerebral hemorrhage and initial systolic blood pressure of 220 mm Hg or more vs less than 220 mm Hg. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the Antihypertensive Treatment of Acute Cerebral Hemorrhage-II trial was performed in November 2019 on data from the multicenter randomized clinical trial, which was conducted between May 2011 to September 2015. Patients with intracerebral hemorrhage and initial systolic blood pressure of 180 mm Hg or more, randomized within 4.5 hours after symptom onset, were included. INTERVENTIONS: Intravenous nicardipine infusion titrated to goals. MAIN OUTCOMES AND MEASURES: Neurological deterioration and hematoma expansion within 24 hours and death or severe disability at 90 days, plus kidney adverse events and serious adverse events until day 7 or hospital discharge. RESULTS: A total of 8532 patients were screened, and 999 individuals (mean [SD] age, 62.0 [13.1] years; 620 men [62.0%]) underwent randomization and had an initial SBP value. Among 228 participants with initial systolic blood pressures of 220 mm Hg or more, the rate of neurological deterioration within 24 hours was higher in those who underwent intensive (vs standard) systolic blood pressure reduction (15.5% vs 6.8%; relative risk, 2.28 [95% CI, 1.03-5.07]; P = .04). The rate of death and severe disability (39.0% vs 38.4%; relative risk, 1.02 [95% CI, 0.73-1.78]; P = .92) was not significantly different between the 2 groups. There was a significantly higher rate of kidney adverse events in participants randomized to intensive systolic blood pressure reduction (13.6% vs 4.2%; relative risk, 3.22 [95% CI, 1.21-8.56]; P = .01), but no difference was observed in the rate of kidney serious adverse events. CONCLUSIONS AND RELEVANCE: The higher rate of neurological deterioration within 24 hours associated with intensive treatment in patients with intracerebral hemorrhage and initial systolic blood pressure of 220 mm Hg or more, without any benefit in reducing hematoma expansion at 24 hours or death or severe disability at 90 days, warrants caution against generalization of recommendations for intensive systolic blood pressure reduction.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Qureshi AI, Huang W, Lobanova I, et al. Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure: Post Hoc Analysis of a Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 32897310. doi:10.1001/jamaneurol.2020.3075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。